Improve gut microbiome: a new horizon of cancer therapy.
作者信息
Fukui Hiroshi
机构信息
Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, Nara, Japan.
出版信息
Hepatobiliary Surg Nutr. 2017 Dec;6(6):424-428. doi: 10.21037/hbsn.2017.08.04.
Abstract
摘要
相似文献
1
Improve gut microbiome: a new horizon of cancer therapy.改善肠道微生物群：癌症治疗的新前沿。
Hepatobiliary Surg Nutr. 2017 Dec;6(6):424-428. doi: 10.21037/hbsn.2017.08.04.
2
The gut microbiome and aquatic toxicology: An emerging concept for environmental health.肠道微生物组与水生毒理学：环境健康领域的新兴概念。
Environ Toxicol Chem. 2018 Nov;37(11):2758-2775. doi: 10.1002/etc.4249. Epub 2018 Oct 5.
3
[The Relationship between Gut Microbiome, Immune System, and Cancer].[肠道微生物群、免疫系统与癌症之间的关系]
Gan To Kagaku Ryoho. 2019 Dec;46(12):1807-1813.
4
GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons.肠道微生物群-肠道生态失调-动脉高血压：新视野
Curr Hypertens Rev. 2019;15(1):40-46. doi: 10.2174/1573402114666180613080439.
5
The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review.肠道微生物组、症状和癌症患儿的靶向干预：系统评价。
Support Care Cancer. 2018 Feb;26(2):427-439. doi: 10.1007/s00520-017-3982-3. Epub 2017 Nov 22.
6
Gut microbiome modulates efficacy of immune checkpoint inhibitors.肠道微生物组调节免疫检查点抑制剂的疗效。
J Hematol Oncol. 2018 Mar 27;11(1):47. doi: 10.1186/s13045-018-0592-6.
7
Gut Microbiome and the Response to Immunotherapy in Cancer.肠道微生物群与癌症免疫治疗反应
Discoveries (Craiova). 2018 Sep 30;6(3):e84. doi: 10.15190/d.2018.4.
8
Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer.肠道微生物组：结直肠癌免疫治疗的有前途的生物标志物。
Int J Mol Sci. 2019 Aug 25;20(17):4155. doi: 10.3390/ijms20174155.
9
Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.肠道微生物组与非小细胞肺癌对检查点抑制剂的反应-综述。
Crit Rev Oncol Hematol. 2020 Jan;145:102841. doi: 10.1016/j.critrevonc.2019.102841. Epub 2019 Dec 23.
10
Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function.肠道微生物组失调与甲状腺癌和甲状腺结节有关，并与甲状腺功能的临床指标相关。
Endocrine. 2019 Jun;64(3):564-574. doi: 10.1007/s12020-018-1831-x. Epub 2018 Dec 24.
引用本文的文献
1
Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: Bibliometric analysis and global trends.2011年至2022年肠道微生物群与肝细胞癌之间的关联：文献计量分析与全球趋势
Front Oncol. 2023 Mar 30;13:1120515. doi: 10.3389/fonc.2023.1120515. eCollection 2023.
2
Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis.肠道通透性是肝硬化发病机制中的机械变阻器。
Int J Mol Sci. 2021 Jun 28;22(13):6921. doi: 10.3390/ijms22136921.
3
New strain of alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism.新型菌株通过调节肠道微生物群和短链脂肪酸代谢来缓解乙醇引起的肝损伤。
World J Gastroenterol. 2020 Oct 28;26(40):6224-6240. doi: 10.3748/wjg.v26.i40.6224.
4
Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?肠道菌群失调在肝脏疾病中的作用：我们目前了解到了什么？
Diseases. 2019 Nov 12;7(4):58. doi: 10.3390/diseases7040058.
5
Alteration in gut microbiota caused by time-restricted feeding alleviate hepatic ischaemia reperfusion injury in mice.限时喂养引起的肠道微生物组改变可减轻小鼠肝缺血再灌注损伤。
J Cell Mol Med. 2019 Mar;23(3):1714-1722. doi: 10.1111/jcmm.14069. Epub 2018 Dec 26.
本文引用的文献
1
The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.肠道微生物群：肝硬化和肝细胞癌的一种新的潜在驱动力。
United European Gastroenterol J. 2017 Nov;5(7):944-953. doi: 10.1177/2050640617705576. Epub 2017 May 8.
2
The role of the microbiome in cancer development and therapy.微生物群落在癌症发展和治疗中的作用。
CA Cancer J Clin. 2017 Jul 8;67(4):326-344. doi: 10.3322/caac.21398. Epub 2017 May 8.
3
Regulatory T cells, especially ICOS FOXP3 regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival.调节性T细胞，尤其是诱导共刺激分子（ICOS）FOXP3调节性T细胞，在肝细胞癌微环境中增多，并预示着生存期缩短。
Sci Rep. 2016 Oct 11;6:35056. doi: 10.1038/srep35056.
4
Gut Microbiota and Host Reaction in Liver Diseases.肝脏疾病中的肠道微生物群与宿主反应
Microorganisms. 2015 Oct 28;3(4):759-91. doi: 10.3390/microorganisms3040759.
5
Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.肝硬化患者中与肝细胞癌存在相关的肠道微生物群特征
Transplant Proc. 2016 Jun;48(5):1687-91. doi: 10.1016/j.transproceed.2016.01.077.
6
Microbiome and Anticancer Immunosurveillance.微生物组与抗肿瘤免疫监视
Cell. 2016 Apr 7;165(2):276-87. doi: 10.1016/j.cell.2016.03.001.
7
Taurocholic acid metabolism by gut microbes and colon cancer.肠道微生物对牛磺胆酸的代谢与结肠癌
Gut Microbes. 2016 May 3;7(3):201-15. doi: 10.1080/19490976.2016.1150414. Epub 2016 Mar 22.
8
Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice.经益生菌调节的肠道微生物群可抑制小鼠肝细胞癌的生长。
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1306-15. doi: 10.1073/pnas.1518189113. Epub 2016 Feb 16.
9
Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells.微生物与肠上皮细胞黏附诱导Th17细胞
Cell. 2015 Oct 8;163(2):367-80. doi: 10.1016/j.cell.2015.08.058. Epub 2015 Sep 24.
10
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.肥胖诱导的肠道微生物代谢物通过衰老分泌组促进肝癌。
Nature. 2013 Jul 4;499(7456):97-101. doi: 10.1038/nature12347. Epub 2013 Jun 26.
Zotero 插件